AbCellera Biologics Inc.

conference call. My name is Cameron and I'll facilitate the audio portion of today's interactive broadcast. All lines will be muted during the presentation portion of the call with an opportunity for questions and answers at the end. If you would like to ask a question, please press star followed by one on your telephone keypad. And if you are having any issues during the call, please press star followed by zero on your telephone keypad. At this time, I would like to turn the call over to Trent Steinmark, Abcelera's Chief Legal and Compliance Officer. You may proceed. Thank you.

Hello, everyone. Thank you for joining us for Abcelera's third quarter 2025 earnings call. I'm Trent Steimart, Abcelera's chief legal and compliance officer. Dr. Carl Hansen, Abcelera's president and CEO, and Andrew Booth, Abcelera's chief financial officer, are also on today's call. During this call, we anticipate making projections and forward-looking statements based on our current expectations and in accordance with the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Our actual results could differ materially due to several factors outlined in our latest Form 10-K and subsequent Forms 10-Q and 8-Q filed with the Securities and Exchange Commission. EBCLR is not obligated to update any forward-looking statements, whether due to new information, future events, or otherwise. Our presentation today, our earnings press release, and our SEC filings are available on our investor relations website. The information we provide about our pipeline is intended for the investment community and is not promotional. As we transition to our prepared remarks, please note that all dollars referred to during the call are U.S. dollars. After our prepared remarks, we will open the lines for questions and answers. Now, I'll turn the call over to Carl.

Thanks Trinh, and thank you everyone for joining us today. Last quarter, we completed our transition from a platform company to a clinical stage biotech with the initiation of our phase one clinical trials for ABCL635 and ABCL575. Both trials are progressing to plan and remain on track for readouts next year. I'm pleased to report that this quarter, we have also started activities at our new clinical manufacturing facility, and we have substantially completed our platform investments. We ended the quarter with approximately $680 million in available liquidity to execute in our strategy. And as we close out the year, we are confident in achieving all our corporate priorities, including advancing at least one more development candidate into IND-enabling studies. A highlight of this quarter was the appointment of Dr. Sarah Neumburg as Chief Medical Officer. Sarah is a physician scientist with over 20 years of clinical drug development experience. She has a broad Pardon me. She has worked across a broad range of modalities and indications and has led programs through all stages of development from discovery through to approval. You can expect Sarah to join future earnings calls to provide updates on our clinical pipeline. With Sarah taking the helm, Dr. Jeff Nickel will be stepping down as our SVP of development. I'd like to thank Jeff for his leadership in building development as we transitioned from a platform company to a clinical stage biotech. And with that, I will hand it over to Andrew to discuss our financials. Andrew?